Table 2: Phase-III studies with pegylated liposomal doxorubicin (PLD) as a single agent or in combination regimens.

AuthorDose/scheduleClinical setting
PFI (mts)
No. ptsRR (%)PFS (median)
(mts)
OS

O’Byrne et al. [47] PLD (50 mg/m2) q28 versus
PTX (175 mg/m2) q21
214
REC10717.8 5.411.4
10722.46.0 14.0
Gordon et al. [48, 49]PLD (50 mg/m2) d1, q28 versus
TPT (1.5 mg/m2) d1–5 q21
RES 255
130
125
12.3
6.5
2.3
3.4
8.9
10.3
Mutch et al. [50]PLD (50 mg/m2) d1, q28 versus
GEM (1,000 mg/m2) d1, 8, q21
RES195
96
99
8.3
6.1
3.6
3.1
12.7
13.5
Ferrandina et al. [51]PLD (40 mg/m2) q28 versus
GEM (1,000 mg/m2) d1, 8, 15 q28
RES153
76
77
16
29
4.0
5.0
14
12.7* 
Monk et al. [52]
OVA-301
TRAB (1.1 mg/m2) d1, q21 versus
PLD (50 mg/m2) q28
ALL67228.0* 
19.0
7.3* 
5.9
20.5
19.4
PLD (30 mg/m2) d1
TRAB (1.1 mg/m2) d1, q21 versus PLD (50 mg/m2) q28
SEN430
335
337
35* 
23
9.2* 
7.5

Markman et al. [53]
SWOG SO200
PLD (30 mg/m2) d1/CBDCA (AUC 5) d1, q28 versus
CBDCA (AUC 5) d1, q28
SEN
6–24 mts
31
30
59* 
28
12* 
8
31
18
Pujade-Lauraine et al. [54]
CALYPSO
PLD (30 mg/m2) d1
JM8 (AUC 5) d1, q28 versus
PTX (175 mg/m2) d1
JM8 (AUC 5) d1, q21
SEN
>6 mts
467
509

11.3* 
9.4


GEM: gemcitabine; OS: overall survival; PFS: progression-free survival; PTX: paclitaxel; REC: not otherwise specified recurrent disease; RES: platinum-resistant recurrent disease; RR: response rate; SEN: platinum-sensitive recurrent disease; TRAB: trabectedin; q: every; d: day. *Statistically significant.